Tag: cancer screening test

Gene Testing Lab Goes ‘Cold Turkey,’ Stops Billing Health Plans

By Joseph Burns, from the Volume XXIII, No. 6 - May 2, 2016 issue

CEO SUMMARY: Last year, Kailos Genetics stopped collecting third-party payment, dropped its prices sharply, and started marketing its genetic-screening tests directly to consumers and physicians. At the time, 100% of its revenue came from third-party payers. Today, it gets 100% of its revenue from consumers. After eliminating third-party payment, revenue dropped precipitously, but is now

View Article

New ADLT Payment Rate May Force Lab to Close

By Joseph Burns, from the Volume XXII NO. 15 - October 26, 2015 issue

CEO SUMMARY: Four Medicare Administrative Contractors currently pay $2,821 for CareDx’s AlloMap test. But under the proposal that CMS issued last month to overhaul the clinical lab fee schedule, CareDx would get only $644. Such a steep price cut would put the lab out of business because the payment would be lower than the cost

View Article

May 06, 2013 “Intelligence: Late Breaking Lab News”

By Robert Michel, from the Volume XX No. 6 - May, 6, 2013 issue

Much is happening in the anatomic pathology market in the Pacific Northwest. PAML, LLC (Spokane, Washington), and CellNetix (Seattle, Washington) finally executed the agreement whereby PAML made an equity investment in CellNetix. Now, the two lab companies will collaborate on developing a reference and esoteric anatomic pathology testing service with national ambitions. Within days of

View Article

Leica, Aperio, Myriad, AMP, Hologic, Gen-Probe

By Robert Michel, from the Volume XIX No. 12 - August 27, 2012 issue

LEICA BIOSYSTEMS TO ACQUIRE APERIO
FOR THE SECOND TIME IN AS MANY YEARS, a global leader in histology systems and products has announced that it will acquire one of the leading digital pathology companies. This time it is Leica Biosystems of Nussloch, Germany, which will purchase Aperio Technologies, Inc., of Vista, California.

Founded by Dirk Soenksen in

View Article

Sonic Health Wins Irish Contract for Pap Testing

By Robert Michel, from the Volume XVII No. 7 - May 10, 2010 issue

CEO SUMMARY: Evidently the Irish Health Service is satisfied with its decision to outsource all the nation’s cervical cancer screening tests. In recent weeks, it announced that two international laboratory companies would handle Pap testing for the next two years. Sonic Healthcare, Ltd., won a contract to perform 25% of Ireland’s 300,000 Pap tests annually.

View Article

Irish Labs Are at an Important Crossroads

By R. Lewis Dark, from the Volume XVII No. 7 - May 10, 2010 issue

GLOBAL OUTSOURCING OF CLINICAL LABORATORY TESTING IN IRELAND has entered its second phase. The Irish Health Service Executive (HSE) granted Quest Diagnostics Incorporated a contract for an additional two-years of cervical cancer screening tests while awarding 25% of the nation’s annual Pap testing to Sonic Healthcare Ltd. in a similar two-year contract.

These developments are significant,

View Article

Irish Labs Appeal to Keep Pap Smear Expertise

By Robert Michel, from the Volume XVI No. 12 - August 31, 2009 issue

CEO SUMMARY: In Ireland, pathologists are asking the government to return enough Pap tests back to the country to support and sustain medical training programs in gynecologic cytology. It was 2008 when the Irish government outsourced all Pap testing to a U.S. lab company. That forced Ireland’s major cytology laboratories to shut down their cervical

View Article

San Diego MSA Selected For Medicare Lab Demo

By Robert Michel, from the Volume XIV No. 15 - October 29, 2007 issue

CEO SUMMARY: Earlier this month, CMS revealed its selection of the first of two sites for the Medicare Competitive Bidding Demonstration Project for Laboratory Testing Services. It will be the San Diego-Carlsbad-San Marcos MSA (metropolitan statistical area). An assessment of this MSA reveals a number of reasons why it is likely that CMS believes it

View Article

Are Two Blood Brothers Using Economic Clout?

By Robert Michel, from the Volume X No. 10 - July 28, 2003 issue

CEO SUMMARY: Quest Diagnostics Incorporated and Laboratory Corporation of America now dominate the national marketplace for testing referred by physicians’ offices. Release of their second quarter earnings reports provides the first look at their performance following the acquisitions in 2002 which removed American Medical Laboratories, Dynacare, DIANON Systems, and Unilab from the marketplace.

WITH THE RELEASE

View Article

Digene, Ivax Diagnostics, Myriad Genetics, Bioscientia, LabOne, Aetna

By Robert Michel, from the Volume VIII No.10 - July 23, 2001 issue

ROTARY CLUBS LAUNCH MEXICO-BASED CERVICAL SCREENING EFFORT
IN MEXICO, Rotary International will attack the problem of cervical cancer among Mexican women by supporting a screening program that utilizes human papillomavirus (HPV) testing.

Called “Test for Life,” the program will be run by local Rotary clubs in Mexico and the United States. It is funded by a grant

View Article

Volume XXVI No. 2 – February 4, 2019

NOW THAT MOST HOSPITALS ARE INCLUDED as applicable laboratories that must report their PAMA private payer lab test price data to the Centers for Medicare and Medicaid Services, managers of those labs will benefit from the incisive analysis in this issue of the lessons learned during the 2017 PAMA reporting cycle. THE DARK REPORT further offers recommendations on how labs can do a better job of gathering and reporting their own data to CMS. Also, TDR delivers an exclusive analysis of why the Government Accounting Office's assertion that CMS will be paying billions more for Part B clinical lab tests is simply wrong.

See the full table of contents

Tag: cancer screening test

Enter Your Login Credentials